The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II trial investigating the safety and efficacy of autologous TAC T cells targeting HER2 in relapsed or refractory solid tumors.
 
Benjamin L. Schlechter
No Relationships to Disclose
 
Daniel Olson
Consulting or Advisory Role - MJH Life Sciences; Novartis
 
Samuel Saibil
Honoraria - Immunocore
Consulting or Advisory Role - Novartis
Speakers' Bureau - Sanofi
 
Mridula Annette George
Consulting or Advisory Role - OBI Pharma; Seagen
Research Funding - Incyte; Oncolytics
 
Kelly Gruber
No Relationships to Disclose
 
Riemke Bouvier
No Relationships to Disclose
 
Brooke Pieke
No Relationships to Disclose
 
Jill Geisburger
No Relationships to Disclose
 
Kara M. Moss
Employment - Triumvira Immunologics, Inc
Stock and Other Ownership Interests - Triumvira Immunologics, Inc
Travel, Accommodations, Expenses - Triumvira Immunologics, Inc
 
Nathan Ternus
Employment - Sumitomo Dainippon Pharma; Triumvira Immunologics, Inc
Stock and Other Ownership Interests - Triumvira Immunologics, Inc
Travel, Accommodations, Expenses - Triumvira Immunologics, Inc
 
Deyaa R Adib
Employment - Triumvira Immunologics, Inc
Leadership - Triumvira Immunologics, Inc
Stock and Other Ownership Interests - Triumvira Immunologics, Inc
Consulting or Advisory Role - Eagle Pharmaceuticals; Epizyme; Ikena Oncology; Mythic Therapeutics; OBI Pharma; Rain Therapeutics
Research Funding - Eagle Pharmaceuticals; Epizyme; Ikena Oncology; Mythic Therapeutics; OBI Pharma; Rain Therapeutics
Travel, Accommodations, Expenses - Eagle Pharmaceuticals; Epizyme; Ikena Oncology; Mythic Therapeutics; OBI Pharma; Rain Therapeutics
 
Ecaterina Elena Dumbrava
Consulting or Advisory Role - Bolt Biotherapeutics
Research Funding - Aileron Therapeutics (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Bolt Biotherapeutics (Inst); Compugen (Inst); Gateway Foundation (Inst); Immunocore (Inst); Immunomedics/Gilead (Inst); Mereo BioPharma 5 (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); TRACON Pharma (Inst); Triumvira Immunologics, Inc (Inst); Unum Therapeutics (Inst)